Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Total Non-Current Liabilities data on record, last reported at $130.1 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed 0.04% year-over-year to $130.1 million; the TTM value through Sep 2025 reached $130.1 million, changed 0.04%, while the annual FY2024 figure was $124.8 million, 2.73% down from the prior year.
  • Total Non-Current Liabilities reached $130.1 million in Q3 2025 per BTAI's latest filing, down from $130.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $139.0 million in Q3 2023 and bottomed at $82.0 million in Q2 2022.
  • Average Total Non-Current Liabilities over 4 years is $125.3 million, with a median of $129.2 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 61.19% in 2023, then decreased 6.38% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $126.7 million in 2022, then grew by 1.24% to $128.3 million in 2023, then dropped by 2.73% to $124.8 million in 2024, then grew by 4.25% to $130.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $130.1 million in Q3 2025, $130.8 million in Q2 2025, and $125.5 million in Q1 2025.